NCT00177242 is a Phase 2 clinical trial of Gefitinib in Cancer, sponsored by University of Pittsburgh.

Who is sponsoring NCT00177242?

NCT00177242 is sponsored by University of Pittsburgh.

What drugs are being tested in NCT00177242?

Interventions in NCT00177242: Gefitinib.

Is NCT00177242 still recruiting?

NCT00177242 is currently completed. Last updated 15 January 2016.

Last reviewed 2016-01-15 · How we verify

NCT00177242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Completed Phase 2 Last updated 15 January 2016

What this trial tests

Phase 2 trial testing Gefitinib in Cancer in 45 participants. Completed in 1 December 2006.

Timeline

1 September 2004

1 December 2006

Quick facts

Lead sponsor	University of Pittsburgh
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	1 September 2004
Estimated completion	1 December 2006
Sites	1 location across United States

Drugs / interventions tested

Gefitinib (gefitinib) — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.

Sponsor's own description

This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers.
Liang X, Weng J, You Z, Wang Y, et al · · 2025 · cited 50× · PMID 40847302 · DOI 10.1186/s12943-025-02375-x
Exploring the Thioredoxin System as a Therapeutic Target in Cancer: Mechanisms and Implications.
Seitz R, Tümen D, Kunst C, Heumann P, et al · · 2024 · cited 26× · PMID 39334737 · DOI 10.3390/antiox13091078
Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target.
Brandl N, Seitz R, Sendtner N, Müller M, et al · · 2025 · cited 7× · PMID 40867898 · DOI 10.3390/antiox14081002

Verify or expand the search:

Other trials of Gefitinib

Trials testing the same drug.

NCT03866499 — A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients · Phase 3 · active not recruiting
NCT04425187 — Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC · Phase 2 · unknown
NCT04358562 — Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Trea · Phase 2 · unknown
NCT04239833 — A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · Phase 3 · unknown
NCT04143607 — ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC · Phase 3 · active not recruiting

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00177242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 15 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00177242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing